Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA4 | P22748 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHKB | Q9Y259 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846601 | 0.83 | ENPP1 (0.56) | POLBMAPTMEN1KMT2AENPP1 | |
| SCHEMBL24847435 | 0.80 | POLB (0.55) | POLBMAPTMEN1KMT2AENPP1 | |
| SCHEMBL31562918 | 0.80 | POLB (0.62) | POLBMAPTMEN1KMT2AENPP1 | |
| SCHEMBL24846434 | 0.78 | ALDH1A1 (0.57) | CA2CA9CA1POLBMAPT | |
| SCHEMBL31562858 | 0.78 | POLB (0.55) | POLBMAPTMEN1KMT2AENPP1 | |
| SCHEMBL24846631 | 0.76 | ENPP1 (0.49) | CA2CA4CA9CA1POLB | |
| SCHEMBL24847424 | 0.76 | POLB (0.62) | POLBMAPTMEN1KMT2AENPP1 | |
| SCHEMBL6694591 | 0.76 | EGFR (0.60) | CA2CA4CA9CA1EGFR | |
| SCHEMBL11862441 | 0.75 | ADORA2A (0.60) | — | |
| SCHEMBL24846598 | 0.74 | MAPT (0.56) | POLBMAPTMEN1KMT2AENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002387-A1 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | ATEN PORUS LIFESCIENCES PVT. LTD. (IN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002387-A1 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | ENPP1, ENPP3, PNP | CA2 4263/4885CA4 4769/4885CA9 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.